The 2015 Centers for Disease Control Sexually Transmitted Disease treatment guidelines currently recommend a single 2-g dose of oral metronidazole as the preferred regimen for treatment of trichomoniasis in human immunodeficiency virus (HIV)-negative women. Mounting recent evidence has shown that the 7-day oral metronidazole dosing regimen is more efficacious than the single 2-g dose. This commentary reviews the implications associated with these new data and discusses issues surrounding it that should be considered moving forward.
This commentary reviews the implications associated with new trichomonas treatment data in women, which suggests that all women should be treated with 7 days of oral metronidazole.
From the *Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL; and
†Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
Conflicts of Interest: C.A.M. is a consultant for Lupin Pharmaceuticals and has received honoraria from Roche Diagnostics.
Sources of Funding: The National Institute of Allergy and Infectious Diseases (NIAID) (K23AI106957-01A1) currently funds Christina A. Muzny, MD, MSPH. Patricia Kissinger is funded by NIAID (R01AI097080-01A1) and NIAID/National Institute of Child Health and Human Development (R01HD086794).
Correspondence: Christina A. Muzny, MD, MSPH, Division of Infectious Diseases, University of Alabama at Birmingham, ZRB 242, 1530 3rd Ave. South, Birmingham, AL 35294. E-mail: email@example.com.
Received for publication October 8, 2018, and accepted November 26, 2018.